Cover Image
市場調查報告書

抗體相關的各種合作契約:契約條件・同意内容

Global Antibody Partnering Terms and Agreements 2010-2016: Deal Trends, Players and Financials

出版商 Current Partnering, a division of Wildwood Ventures Limited 商品編碼 234470
出版日期 內容資訊 英文 829 Pages (including appendices)
商品交期: 最快1-2個工作天內
價格
Back to Top
抗體相關的各種合作契約:契約條件・同意内容 Global Antibody Partnering Terms and Agreements 2010-2016: Deal Trends, Players and Financials
出版日期: 2016年11月18日 內容資訊: 英文 829 Pages (including appendices)
簡介

本報告書內容包括:抗體相關各種合作契約的調查分析、近年的各種契約趨勢、大規模契約及大型醫藥品事業者的契約概要、契約種類・開發階段・技術種類・治療/疾病科目分類的索引等彙整、內容綱要摘記如下:

實施摘要

第1章 介紹

第2章 抗體相關各種契約趨勢

  • 介紹
  • 過去數年的抗體相關合作
  • 大型製藥公司的契約活動
  • 抗體相關事業的非積極性大型製藥公司
  • 抗體相關合作:各種契約種類
  • 抗體相關合作:各種疾病區分
  • 合作:各種抗體種類
  • 平均的契約條件

第3章 主要契約

  • 主要契約:各種交易金額
  • 大型製藥事業者的主要契約

第4章 大型醫藥品企業的各種契約

  • 大型製藥企業的介紹

第5章 契約名錄

  • 簡介
  • 各開發階段
    • 藥物發明
    • 前臨床
    • 階段I
    • 階段II
    • 階段III
    • 申請登記
    • 市售
  • 各類型契約
    • 資產購買
    • 權利讓
    • 大醫藥品企業的對外授權
    • 共同開發
    • 共同R&D
    • 共同行銷
    • 服務契約
    • 共同促銷
    • CRADA
    • 交叉授權
    • 開發
    • 流通銷售
    • 股票購買
    • 評估
    • 轉讓
    • 合資企業
    • 授權
    • 貸款
    • 製造
    • 行銷
    • 材料轉移
    • 選擇
    • 推銷
    • 研究
    • 專利稅融資
    • 和解相關
    • 消耗
    • 輔助許可證
    • 供給
    • 技術轉移
    • 契約解除
  • 治療科目別
    • 中樞神經
    • 皮膚科
    • 消化器官
    • 遺傳基因疾病
    • 泌尿生殖系統
    • 婦產科
    • 血液
    • 住院照護
    • 免疫疾病
    • 感染疾病
    • 代謝性疾病
    • 肌肉骨骼系統疾病
    • 癌症
    • 眼科
    • 小兒科
    • 精神科
    • 公共衛生
    • 呼吸系統
  • 不同技術抗體
    • 抗體
    • 抗體藥物複合體
    • 單株抗體
    • 嵌合單株抗體
    • 人體化單株抗體
    • 完全人體單株抗體
    • 鼠源性單株抗體
    • 多株抗體等

第6章 合作機會

  • 線上夥伴連結
  • 夥伴連結活動
  • 相關資料

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: CP2113

The Global Antibody Partnering Terms and Agreements 2010 to 2016 report provides comprehensive understanding and unprecedented access to the Antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors Antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:

  • Antibodies
  • Antibody-drug conjugates
  • Monoclonal antibodies
  • Murine mAb
  • Chimeric mAb
  • Humanized mAb
  • Human aAb
  • Polyclonal Antibodies

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This report contains over 1,200 links to online copies of actual Antibody deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of Antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Antibody dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Antibody deals since 2010. Deals are listed by headline value, signed by big pharma, most active Antibody dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Antibody dealmaking with a brief summary followed by a comprehensive listing of Antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Antibody partnering deals signed and announced since Jan to 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of Antibody partnering deals signed and announced since Jan to 2010. The chapter is organized by specific Antibody technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Antibody partnering company A-Z, deal type definitions and Antibody partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Antibody partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Antibody technologies and products.

Key benefits

Global Antibody Partnering Terms and Agreements 2010 to 2016 provides the reader with the following key benefits:

  • In-depth understanding of Antibody deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Antibody agreements with real life case studies
  • Detailed access to actual Antibody contracts enter into by the leading fifty bigpharma companies
  • Insight into the terms included in a Antibody agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Antibody Partnering Terms and Agreements 2010 to 2016 is intended to provide the reader with an in-depth understanding and access to Antibody trends and structure of deals entered into by leading companies worldwide.

Global Antibody Partnering Terms and Agreements 2010 to 2016 includes:

  • Trends in Antibody dealmaking in the biopharma industry since 2010
  • Analysis of Antibody deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Antibody deals
  • Access to over 1,200 Antibody online deal records
  • The leading Antibody deals by value since 2010
  • Most active Antibody dealmakers since 2010
  • The leading Antibody partnering resources

In Global Antibody Partnering Terms and Agreements 2010 to 2016, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Antibody Partnering Terms and Agreements 2010 to 2016 report provides comprehensive access to available deals and contract documents for over 1,200 Antibody deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise Antibody rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Antibody Partnering 2010-2016 provides the reader with the following key benefits:

  • In-depth understanding of antibody deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of antibody agreements with numerous real life case studies
  • Comprehensive access to over 1,200 actual antibody deals entered into by the world's biopharma companies, together with contract documents if available
  • Detailed access to actual antibody contracts enter into by the leading companies
  • Identify leading antibody deals by value since 2010
  • Identify the most active antibody dealmakers since 2010
  • Insight into the terms included in a antibody agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in antibody dealmaking

  • 2.1. Introduction
  • 2.2. Antibody partnering over the years
  • 2.3. Most active antibody dealmakers
  • 2.4. Antibody partnering by deal type
  • 2.5. Antibody partnering by therapy area
  • 2.6. Deal terms for antibody partnering
  • 2.6.1 Antibody partnering headline values
  • 2.6.2 Antibody deal upfront payments
  • 2.6.3 Antibody deal milestone payments
  • 2.6.4 Antibody royalty rates

Chapter 3 - Leading antibody deals

  • 3.1. Introduction
  • 3.2. Top antibody deals by value

Chapter 4 - Most active antibody dealmakers

  • 4.1. Introduction
  • 4.2. Most active antibody dealmakers
  • 4.3. Most active antibody partnering company profiles

Chapter 5 - Antibody contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Antibody contracts dealmaking directory

Chapter 6 - Antibody dealmaking by technology type

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

Appendix 1 - Antibody deals by company A-Z

Appendix 2 - Antibody deals by stage of development

  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Regulatory
  • Marketed
  • Formulation

Appendix 3 - Antibody deals by deal type

  • Asset purchase
  • Assignment
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Co-market
  • Co-promotion
  • CRADA
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Loan
  • Manufacturing
  • Marketing
  • Material transfer
  • Option
  • Promotion
  • Research
  • Settlement
  • Spin out
  • Sub-license
  • Supply
  • Technology transfer
  • Termination

Appendix 4 - Antibody deals by therapy area

  • Cardiovascular
  • Central Nervous System
  • Dental
  • Dermatology
  • Gastrointestinal
  • Hematology
  • Hospital care
  • Immunology
  • Infectives
  • Metabolic
  • Musculoskeletal
  • Obstetrics
  • Oncology
  • Ophthalmics
  • Orphan disease
  • Pediatrics
  • Psychiatry
  • Respiratory

Appendix 5 -Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Therapeutic antibody definitions
  • Figure 2: Antibody partnering since 2010
  • Figure 3: Active antibody dealmaking activity- 2010 to 2016
  • Figure 4: Antibody partnering by deal type since 2010
  • Figure 5: Antibody partnering by disease type since 2010
  • Figure 6: Antibody deals with a headline value
  • Figure 7: Antibody deals with an upfront value
  • Figure 8: Antibody deals with a milestone value
  • Figure 9: Antibody deals with a royalty rate value
  • Figure 10: Top antibody deals by value since 2010
  • Figure 11: Most active antibody dealmakers 2010 to 2016
  • Figure 12: Online partnering resources
  • Figure 13: Forthcoming partnering events
Back to Top